Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Paolo G. Casali(Fondazione IRCCS Istituto Nazionale dei Tumori), Martin Robinson(Weston Park Cancer Centre), Jean‐Yves Blay(Université Claude Bernard Lyon 1), N. Abecassis, Thomas Brodowicz(Vienna General Hospital), Suzanne E. J. Kaal(Radboud University Nijmegen), Angelo Paolo Dei Tos(University of Padua), Hans Gelderblom(Leiden University Medical Center), R. Biagini(Tumori Foundation), Stefan Bielack(Olgahospital), Maria A. Pantaleo(Azienda USL di Bologna), Sebastian Bauer(Science for Life Laboratory), Virginia Ferraresi(Cancer Institute (WIA)), Kateřina Kopečková(University Hospital in Motol), Rick L. Haas(Leiden University Medical Center), Ofer Merimsky(Tel Aviv Sourasky Medical Center), Mikael Eriksson(Herlev Hospital), Michael Montemurro(University Hospital of Lausanne), A. Bassim Hassan(Kassala University), Iwona Ługowska(The Maria Sklodowska-Curie National Research Institute of Oncology), Peter Hohenberger(University of Mannheim), I. Boukovinas, Dagmar Adámková Krákorová(Masaryk Memorial Cancer Institute), Peter Reichardt(Helios Hospital Berlin-Buch), Robin L. Jones(Institute of Cancer Research), Giovanni Grignani(Candiolo Cancer Institute), А. А. Феденко(P.A. Hertzen Moscow Oncology Research Institute), Anna Maria Frezza(University of Milan), Ian Judson(Erasmus Hospital), Palma Dileo(University College Hospital), Xavier García del Muro(Institut Català d'Oncologia), Sylvie Bonvalot(Dana-Farber Cancer Institute), Angela Buonadonna(Centro di Riferimento Oncologico), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Rolf D. Issels(LMU Klinikum), Bernd Kasper(Heidelberg University), Judith V.M.G. Bovée(Leiden University Medical Center), Piero Picci(Istituto Ortopedico Rizzoli), Axel Le Cesne(Institut Gustave Roussy), Heikki Joensuu(Orion Corporation (Finland)), Andrea Ferrari(University of Milan), Thierry Gil(Institut Jules Bordet), Silvia Gasperoni(Azienda Ospedaliero-Universitaria Careggi), Alho Hannu(Turku University Hospital), Sophie Piperno‐Neumann(Institut Curie), S. Ferrari(Istituto Ortopedico Rizzoli), Raimondo Piana(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Paul C. Jutte(University Medical Center Groningen)
Cited by 751
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k